Simpson, Eric
Eckert, Laurent
Gadkari, Abhijit
Mallya, Usha G.
Yang, Min
Nelson, Lauren
Brown, Michelle
Reaney, Matt
Mahajan, Puneet
Guillemin, Isabelle
Boguniewicz, Mark
Pariser, David
Funding for this research was provided by:
Sanofi (NA)
Regeneron Pharmaceuticals Inc. (NA)
Article History
Received: 21 May 2019
Accepted: 10 October 2019
First Online: 6 November 2019
Ethics approval and consent to participate
: Patients must have consented online to participate in the real-world study prior to proceeding to completing the baseline questions through a secure online portal. The survey was performed in accordance with the Helsinki Declaration of 1964 and its later amendments and received a full review approval by the New England Independent Review Board in December 2017.
: Not applicable.
: L. Eckert, M. Reaney, I Guillemin, U.G. Mallya, and P. Mahajan are employees and shareholders of Sanofi. A. Gadkari is an employee and shareholder of Regeneron. M. Yang is an employee of the Analysis Group, Inc. which received research funding for the current study. L. Nelson and M. Brown are employees of RTI Health Solutions, which received research funding for the current study. E.L. Simpson has received grants/research support from Amgen, Celgene, Chugai, Galderma, and Regeneron Pharmaceuticals Inc., and is a consultant for Anacor, Asubio, Celgene, Galderma, Genentech, Medicis, and Merck. D.M. Pariser has been a consultant to Abbott Laboratories, Amgen, Asana, Biosciences, LLC, Atacama Therapeutics, Bickel Biotechnology, Biofrontera AG, Celgene Corporation, Dermira, Dermavant Sciences, DUSA Pharmaceuticals, Inc., Eli Lilly and Company, LEO Pharma, US, Merck & Co., Inc., Novartis Pharmaceuticals Corp., Novo Nordisk A/S, Ortho Dermatologics, Peplin Inc., Pfizer Inc., Photocure ASA, Promius Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Sanofi, Stiefel a GSK company, TDM SurgiTech, Inc., TheraVida, Valeant Pharmaceuticals International. M Boguniewicz has received grants from Regeneron Pharmaceuticals, Inc. and has been a consultant for Regeneron Pharmaceuticals, Inc. and Sanofi-Genzyme.